Moderna

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Fortune 500

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

America's Most Innovative Companies

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

WMA 2024-Moderna

World's Most Admired Companies

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

Resilience and the capacity for reinvention have never been more important.

Future 50 2021-Moderna

The Future 50

Future 50

Overall Score

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Culture rank

Process rank

Product rank

Years on list

Previous rank

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Get insights into Moderna including business profile, stock information, news, and rankings from Fortune.

Moderna (MRNA): Company Profile, Stock Price, News, Rankings

legacy

moderna

Companies

Moderna | Fortune

Moderna (MRNA): Company Profile, Stock Price, News, Rankings | Fortune

Beth Greenfield

What you need to know about Moderna’s new COVID vaccine, just approved by the FDA

/well/2025/06/02/moderna-new-covid-vaccine-approved-by-fda-what-to-know/

The Associated Press

Trump administration cancels $766 million contract with Moderna to develop vaccine against pandemic flu viruses

/2025/05/29/trump-cancels-766-million-contract-moderna-develop-vaccine-pandemic-flu-viruses/

Sara Braun

This Moderna leader uses AI to resolve conflict on the executive team—all before it even happens 

/2025/05/19/moderna-leader-ai-resolve-conflictexecutive-teamall-before-it-happens/

Sasha Rogelberg

Moderna and Novavax shares plunge after key FDA official steps down, citing discord with RFK Jr. who he says ‘wishes subservient confirmation of his misinformation and lies’

/2025/03/31/moderna-novavax-stock-price-fda-resignation-rfk-jr-vaccine/

Lindsey Leake

Experts sound the alarm as Ohio farmworker’s bird flu sparks fear it’s the next pandemic

/well/article/bird-flu-ohio-farm-worker-avian-influenza-public-health-threat/

What you need to know about Moderna's new COVID vaccine, just approved by the FDA

https://fortune.com/well/2025/06/02/moderna-new-covid-vaccine-approved-by-fda-what-to-know/?itm_source=parsely-api

Marion Halftermeyer

Bloomberg

A CEO abruptly resigned from a board after leaked emails reportedly showed inappropriate influence

https://fortune.com/2024/07/26/rubenstein-ceo-private-equity-resigned-leaks-emails-alaska/?itm_source=parsely-api

As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines

https://fortune.com/well/article/bird-flu-vaccine-moderna-mrna-pandemic-influenza-immunization/?itm_source=parsely-api

New COVID vaccines are here. What to know about latest shots in wake of nation’s biggest summer surge

https://fortune.com/well/article/covid-vaccines-updated-2024-2025/?itm_source=parsely-api

RSV can be deadly, especially for older adults. What to know about symptoms and the new vaccine

https://fortune.com/well/article/rsv-vaccine-seniors-older-adults-pfizer-moderna-gsk/?itm_source=parsely-api

Apple, Microsoft, NVIDIA and Moderna are some All-Star companies on the 2024 World’s Most Admired Companies list.

These companies are admired most by business leaders

Fortune's World's Most Admired Companies 2024

Franchise_Lists

Fortune's World's Most Admired Companies list for 2024

Stan Erck's goal is for people to say about Novavax "they’re the best vaccine company".

Novavax CEO on why his Covid vaccine is "demonstrably better" than Pfizer and Moderna

Leadership

Novavax CEO on why his Covid vaccine is better than others

Stan Erck's goal is for people to say about Novavax "they’re the best vaccine company"

stan thank you so much for joining us to talk about your company Novavax and your new covid vaccine. It was only a few months ago that you came out with the fourth vaccine in the U. S. So now you're competing against the fighter vaccine Moderna and johnson and Johnson tell us why would someone turn to the new Novavax vaccine compared to the established ones that have already been on the market for some time. We have some characteristics of our vaccine that make it more attractive. It's it's a very stable vaccine. It's it's it can be used at refrigerated temperatures. You don't have to go through the minus 20 or minus 70 degrees freezing. That makes it easier to use. I think that people recognize that this is a vaccine, a type of vaccine using a protein injected into the arm that that they've gotten all their lives with different vaccines, childhood vaccines and hepatitis vaccines. So so uh it's there's a comfort level and then there's data that suggests that our vaccine may last longer have have greater durability and and give you a breadth of protection as the virus changes over time and you get oh macron be a five and you get the next generation of of virus. It's hopeful that our vaccine is broad enough to protect against all of those. So how would you describe demand for the nova vax vaccine when you launched it a couple of months ago. Orders were weak. And your stock tumbles. What about now? Well you're talking about us. We've we've been in the global market for some time for instance in Korea and Japan were getting in Australia. We're getting a lot of acceptance of the vaccine has been available for a lot longer in the U. S. It's taken longer to get approvals. And so we're just only recently in the market. And so our expectation is that with data that we will be able to increase demand increased market share over the coming not only coming year but years with our vaccine. Well what's your strategy to compete with fighter and more derna? They've been selling millions of vaccines and boosters. And even now for kids, how do you compete with that? Every week? We get new sets of data that shows that that I I think allows me to predict that that our vaccine will be demonstrably better, more differentiated than the current vaccines. You know, it's taking you a little longer to get your vaccine out compared to Pfizer and Moderna. Do you think that even though Novavax has a good product, it's just too late. No, it's not too late. We're unfortunately we're stuck with Covid for a long time. And like flu, Covid is going to be bringing up new surprises to us from year to year. And I think that the vaccine that shows its most effective against these new variants is the one that ultimately will win. And I think that's our vaccine. Well, you mentioned a moment ago that your vaccine is protein based and it's what most people are used to receiving when they get vaccines. Has this made a difference in getting people who have been hesitant to get vaccinated to feel more comfortable using nova vax. Yeah. I think our vaccine would appeal to people who are vaccine hesitant because they don't understand vaccines very well. People were hesitant for because they don't understand the newest technology might just say good. I've been waiting for this and I'll use it. Well, have you gotten any feedback that your vaccine is getting to people who have been holding off from getting vaccinated by your competitors? Yes. We get a lot of feedback if you look at my if you look at my end basket in boxing my computer every day. I get lots of feedback from people who have said explained why they haven't gotten vaccinated for the past year or two. And now they're anxiously going to the pharmacy to get ours. And most people did don't know much about Novavax until Covid. It was a small struggling biotech company. But once the U. S. Government awarded your company more than $1.5 billion to develop a Covid vaccine, you were in the spotlight. You had already been Ceo for 10 years of the company but now suddenly the world was watching you, What was that like for you? We were actually too busy to pay much attention to that. Truthfully. And we went from I think it was january 12th when the gene sequence of covid became known. And we put all of our efforts? We took them off flu and put them on Covid. And truly, the team has been working seven days a week for the last 2.5 years. And there isn't a day that we don't have some meeting including Sundays and we started to face a phase three trial in the US on christmas day, Year before last. And so it's part of our life right now and will be for some time. Well when you started working a serious way on the COVID vaccine, the company had only 150 people. It didn't even have manufacturing capacity but still you were able to transform it into a global vaccine developer. What did it take for you to ramp up operations? A lot of energy. A lot of perseverance. We had early on some data in non human primates that showed that our vaccine worked really, really well and that those data usually translate well into humans and everybody in the scientific community recognize that. So we had lots of people who we had gained credibility and we were able to convince people to open up manufacturing capacity. Unfortunately that takes time. I mean usually it takes many years. We did it in many months. But but nevertheless it still takes time and we've gone from, as you say around 150 people in the U. S. And europe 2.5 years ago. And now we have over 2000 people and several manufacturing sites. How would you describe what you did as ceo to lead the project and to lead the team? I don't think there's anything magical. I think it's it's it's it's relatively easy when you've got, when you've been able to hire a good group of people and your mission is so so clear and and your technology and the tools you have are so unique. The people in the company that have joined the company in the past three years and have been working with it are all equally motivated because as I say, the mission is not just Covid, it's also Covid and flu and other vaccines. I don't have to do anything special to to motivate these people. They're self motivated. So what's next for Novavax? How do you want people describing the company 345 years from now? Nobody's ever built an independent vaccine company in the last 50 years or more. And I think that's exactly what Novavax is headed toward. Um and in five or 10 years I think I think everybody's going to know when they think vaccines they're going to think about Novavax because they're the best vaccine company

Walmart takes the number one spot for the tenth straight year.

Introducing the 2022 Fortune 500 list

Amazon has taken the number two spot behind Walmart.

Watch: Introducing the 2022 Fortune 500 list

The Fortune 500 is America's largest company that's measured by revenue. This is the 68th edition of the Fortune 500. And really the list is synonymous with big business success. The companies in the Fortune 500 this year produced a total of $16.1 trillion $1.8 trillion dollars in profit. That's $16.1 trillion dollars in revenue is equal to two thirds of the GDP of the United States This year. To crack the 500, companies had to have at least $6.4 billion 19% from the year before. And that really shows the strong year that American business had the order of the companies at the top of the Fortune 500 this year stayed the same as last year, walmart was number one amazon number two. Apple, number three Cbs Health, number four and UnitedHealth group number five walmart, the giant retailer based in Bentonville, Arkansas is number one on the Fortune 500 this year. For the 10th consecutive year, Walmart earned $13.7 billion 27th among the entire 500. And it shows that in that retail business, the margins are not nearly as high as for some of these big tech, Apple came in number three on our list, but it is the number one in terms of profit generating companies in America, it's generated $95 billion dollars in profits. So number four, we have CVS Health. It's run by Karen Lynch, she is one of 44 women C. E. O. S in the Fortune 500. She's one of the most powerful women in the world and she's helping one of the most powerful companies in the world. Amazon made another huge leap towards catching up with walmart. It grew its revenues 21% of $470 billion. Amazon's profits also jumped up by more than 50% to $33 billion, nearly three times the profitability of Wal Mart. Amazon of course is one of the companies that really got a big boost over the past year from the pandemic as people turn to online shopping and also from the streaming world from amazon prime to others that use amazon's cloud services. There wasn't much change in the makeup of the top 10 in the Fortune 500 this year, but one notable development was that Exxon mobil jumped from number 10 back up to number six and that was boosted by higher oil prices. Exxon's revenues shot up 57% to around $285 billion last year. The biggest mover in the Fortune 500 this year was Blackstone. The new york based investment house which jumped 295 spots to number 1, 59 in the rankings as its investment portfolios had huge returns in 2021. Another company that made a really big jump in the rankings this year was Carve Ana, Which moved up 193 spots to # 290. Carbonneau is another one of those companies that really benefited during the pandemic. Some other notable trends from the Fortune 500 this year, where we had our first crypto company, you'll notice coin bases on the list for the very first time. Coin base is a big benefactor of the crypto craze were recently, of course, crypto prices have started to sell off and we're not sure if coin base is going to be around on the 500 next year. Moderna jumps onto the list this year and number 1 95 with $18 billion in sales. And Moderna of course, is one of the companies that brought us the M RNA vaccines and it's really brought that company from being a startup with potential to being a Fortune 500 company almost overnight, More than half of the sectors in the Fortune 500 recorded record profits last year, including financials, retail and big tech. In fact, it was an incredibly strong year for the Fortune 500 across the board. Total sales and total profits hit record levels this year, even adjusted for inflation And revenues grew the most since 1975. While profits jumped the most since 2010. One of the things I found most interesting about the list was actually the people on it. They remained relatively unchanged. We saw there were 44 women ceo, this time that's the highest number of women that have ever been on the Fortune 500 list. But it's only three more than last year. We're gonna expect a lot of movement amongst c. E. O. S. In the next year. So I suspect that leadership of the Fortune 500 will be pretty drastically different next year this time around.

Only the Pfizer and Moderna booster shots have been approved.

FDA recommends second booster for ages 50 and older

Health

People 50 and older can get a second Booster dose of the COVID-19 vaccine. This also means that people who have immuno compromised conditions can get 1/5 dose following the three dose primary vaccination series with Pfizer or Moderna and initial booster that was previously authorized for this population. This is we have plenty of supply to ensure that those populations can receive these shots. Um, but what I would say is that if it at some point it becomes recommended that the full the full population. Yes, it requires 1/4 shot. We're going to need additional funding. We're going to need the additional funding we've requested of Congress to be able to provide uh, to provide those shots for the, for the broader population. But we do have the supply uh, and people will be able to go. People in those populations over 50 and up. We'll be able to go and and get those shots. It's possible that people will need to get another vaccine there and getting this booster will not preclude people from getting that booster necessarily If there's evidence that another booster could be of benefit for most people who have been vaccinated and had one booster, your original booster shot is continuing to bribe you with good protection from being hospitalized or dying. If you haven't had a first booster yet. Now's a good time to get one

Moderna

Moderna in Fortune Rankings

Moderna stock chart

Videos